Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET

Journal of Nuclear Medicine

Volumn 50, Issue SUPPL. 1, 2009, Pages

  Dunphy, Mark P S ^a   Lewis, Jason S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Hypoxia; PET; Proliferation; Steroid receptors; Therapy monitoring

Indexed keywords

1 (2' DEOXY 2' FLUORO BETA DEXTRO ARABINOFURANOSYL)THYMINE F 18; 1 AMINO 3 FLUOROCYCLOBUTANECARBOXYLIC ACID F 18; 1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 16BETA FLUORO 5ALPHA DIHYDROTESTOSTERONE F 18; 3' FLUOROTHYMIDINE F 18; ACETIC ACID C 11; CHOLINE C 11; DIACETYLBIS(N4 METHYLTHIOSEMICARBAZONE) CU 60; DIACETYLBIS(N4 METHYLTHIOSEMICARBAZONE) CU 62; DIACETYLBIS(N4 METHYLTHIOSEMICARBAZONE) CU 64; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL F 18; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GEMCITABINE; HEAT SHOCK PROTEIN 90; IBRITUMOMAB TIUXETAN; METHOTREXATE; METHYLMETHIONINE C 11; O (2 FLUOROETHYL)TYROSINE F 18; RADIOPHARMACEUTICAL AGENT; SEX HORMONE BINDING GLOBULIN; TAMOXIFEN; TEMOZOLOMIDE; THYMIDINE KINASE 1; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER SCINTISCANNING; CELL PROLIFERATION; DNA SYNTHESIS; DRUG UPTAKE; GLIOBLASTOMA; HUMAN; HYPOXEMIA; LYMPHOMA; NONHUMAN; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE;

HUMANS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOISOTOPES; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 66149090004     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.057281     Document Type: Review

References (189)

1. Seidlin S, Marinelli L, Oshry E. Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. JAMA. 1946;132: 838-847.
2. Dunn JT, Dunn AD. Update on intrathyroidal iodine metabolism. Thyroid. 2001;11:407-414.
3. 18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91:498-505.
4. Hadj-Djilani NL, Lebtahi NE, Delaloye AB, Laurini R, Beck D. Diagnosis and follow-up of neuroblastoma by means of iodine-123 metaiodobenzylguanidine scintigraphy and bone scan, and the influence of histology. Eur J Nucl Med. 1995;22:322-329.
5. Lastoria S, Maurea S, Caraco C, et al. Iodine-131 metaiodobenzylguanidine scintigraphy for localization of lesions in children with neuroblastoma: comparison with computed tomography and ultrasonography. Eur J Nucl Med. 1993;20: 1161-1167.
6. Parisi MT, Greene MK, Dykes TM, Moraldo TV, Sandler ED, Hattner RS. Efficacy of metaiodobenzylguanidine as a scintigraphic agent for the detection of neuroblastoma. Invest Radiol. 1992;27:768-773.
7. Giammarile F, Lumbroso J, Ricard M, et al. Radioiodinated metaiodobenzylguanidine in neuroblastoma: influence of high dose on tumour site detection. Eur J Nucl Med. 1995;22:1180-1183.
8. Maurea S, Lastoria S, Caraco C, et al. Iodine-131-MIBG imaging to monitor chemotherapy response in advanced neuroblastoma: comparison with laboratory analysis. J Nucl Med. 1994;35:1429-1435.
9. 123I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer. 2008;44:1552-1558.
10. 123Imetaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma. J Clin Oncol. 2004;22:3909-3915.
11. 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol. 2003;21: 2486-2491.
12. Lamberts SW, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med. 1990;323: 1246-1249.
13. Lamberts SW, Hofland LJ, van Koetsveld PM, et al. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy. J Clin Endocrinol Metab. 1990;71:566-574.
14. Blankenberg FG. In vivo detection of apoptosis. J Nucl Med. 2008; 49(suppl):81S-95S.
15. 99mTc-annexin A5. Br J Radiol. 2003;76:553-560.
16. Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med. 2008;49(suppl):64S-80S.
17. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med. 2003;44:2027-2032.
18. Tehrani OS, Douglas KA, Lawhorn-Crews JM, Shields AF. Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2. Eur J Nucl Med Mol Imaging. 2008;35:1480-1488.
19. Bading JR, Shahinian AH, Vail A, et al. Pharmacokinetics of the thymidine analog 2′-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU) in tumorbearing rats. Nucl Med Biol. 2004;31:407-418. (Pubitemid 38490740)
20. O'Neill KL, Hoper M, Odling-Smee GW. Can thymidine kinase levels in breast tumors predict disease recurrence? J Natl Cancer Inst. 1992;84:1825-1828.
21. Ellims PH, Gan TE, Van der Weyden MB. Thymidine kinase isoenzymes in chronic lymphocytic leukaemia. Br J Haematol. 1981;49:479-481.
22. Haveman J, Sigmond J, van Bree C, Franken NA, Koedooder C, Peters GJ. Time course of enhanced activity of deoxycytidine kinase and thymidine kinase 1 and 2 in cultured human squamous lung carcinoma cells, SW-1573, induced by gamma-irradiation. Oncol Rep. 2006;16:901-905.
23. Han T, Fernandez M, Sarkar M, Agarwal RP. 2′, 3′- Dideoxycytidine represses thymidine kinases 1 and 2 expression in T-lymphoid cells. Life Sci. 2004; 74:835-842. (Pubitemid 37501132)
24. Han T, Fernandez M, Sarkar M, Agarwal RP. Arabinosylcytosine downregulates thymidine kinase and induces cross-resistance to zidovudine in T-lymphoid cells. Biochem Biophys Res Commun. 2003;307:564-568.
25. Atkinson DM, Clarke MJ, Mladek AC, et al. Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts. Head Neck. 2008;30:790-799.
26. 18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging. 2002;29:1462-1469.
27. Monazzam A, Josephsson R, Blomqvist C, Carlsson J, Langstrom B, Bergstrom M. Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer. Breast Cancer Res. 2007;9:R45.
28. 18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study. Br J Cancer. 2008;99:481-487.
29. van Waarde A, Been LB, Ishiwata K, Dierckx RA, Elsinga PH. Early response of sigma-receptor ligands and metabolic PET tracers to 3 forms of chemotherapy: an in vitro study in glioma cells. J Nucl Med. 2006;47:1538-1545.
30. Bergstrom M, Monazzam A, Razifar P, Ide S, Josephsson R, Langstrom B. Modeling spheroid growth, PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVP-AUY922. J Nucl Med. 2008;49:1204-1210.
31. Perumal M, Pillai RG, Barthel H, et al. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res. 2006;66:8558-8564. (Pubitemid 44449169)
32. Wei LH, Su H, Hildebrandt IJ, Phelps ME, Czernin J, Weber WA. Changes in tumor metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin Cancer Res. 2008;14:3416-3426.
33. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 3′-deoxy- 3′- fluorothymidine uptake. Nucl Med Biol. 2004;31:419-423.
34. 18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer Res. 2007;67:11463-11469.
35. 3H-fluorothymidine using preclinical tumor models. Clin Cancer Res. 2006;12:4590-4597.
36. 18F]fluorothymidine positron emission tomography. Cancer Res. 2006;66:7621-7629.
37. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003;63:3791-3798.
38. Pillai RG, Forster M, Perumal M, et al. Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945. Cancer Res. 2008;68:3827-3834.
39. Pan MH, Huang SC, Liao YP, et al. FLT-PET imaging of radiation responses in murine tumors. Mol Imaging Biol. 2008;10:325-334.
40. 18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging. 2006;33:412-419.
41. 18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res. 2005;65:4202-4210.
42. 18F-fluorothymidine PET. J Nucl Med. 2005;46:114-120.
43. 18Ffluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med. 2004;45:1754-1758.
44. 188Re radiation in an MCF7 cell line containing dominantnegative mutant p53. Nucl Med Biol. 2007;34:425-432.
45. 18F]FLT. Eur J Nucl Med Mol Imaging. 2007;34:1775-1782.
46. 18F]fluoro-3′-deoxythymidine (FLT). Mol Imaging Biol. 2007;9:340-347.
47. Kasper B, Egerer G, Gronkowski M, et al. Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leuk Lymphoma. 2007;48:746-753. (Pubitemid 46605547)
48. 18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging. 2004;31:720-724.
49. 18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging. 2003;30:1407-1412.
50. 18F]fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer. Clin Cancer Res. 2008;14:4463-4468.
51. Muzi M, Mankoff DA, Grierson JR, Wells JM, Vesselle H, Krohn KA. Kinetic modeling of 3′-deoxy-3′-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med. 2005;46:371-380.
52. 18Ffluorothymidine in patients with gliomas. J Nucl Med. 2006;47:1612-1621.
53. Muzi M, Vesselle H, Grierson JR, et al. Kinetic analysis of 3′-deoxy-3′- fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med. 2005;46:274-282.
54. 18Ffluorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imaging. 2007;34:1003-1011.
55. 18F]3′-deoxy-3′- fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging. 2007;34:878-883.
56. Guillem JG, Chessin DB, Cohen AM, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005;241:829-836.
57. 18F]fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007;25:4714-4721.
58. 18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res. 2007;13:3552-3558.
59. 18F]FMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging. 2005;32:15-22.
60. 18F-fluoro-β-D-arabinofuranosyl) thymine and PET. J Nucl Med. 2007;48: 1436-1441.
61. Brown JM. The hypoxic cell: a target for selective cancer therapy - Eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1999;59:5863-5870.
62. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996; 379:88-91. (Pubitemid 26008141)
63. Höckel M, Schlenger K, Aral B, Mitze M, Schäffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56:4509-4515.
64. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359:843-845.
65. Ballinger JR. Imaging hypoxia in tumors. Semin Nucl Med. 2001;31:321-329.
66. Tatum JL, Kelloff GJ, Gillies RJ, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol. 2006;82:699-757.
67. 99mTc-BnAO (HL-91): a non-nitroaromatic compound for hypoxic cell detection. Int J Radiat Oncol Biol Phys. 1998;42:737-740.
68. 18F]EF1. J Nucl Med. 2000;41:327-336.
69. Cook GJ, Houston S, Barrington SF, Fogelman I. Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG. J Nucl Med. 1998;39:99-103.
70. 18F-fluoroazomycin arabinoside. J Nucl Med. 2005;46:106-113.
71. Tatsumi M, Yutani K, Kusuoka H, Nishimura T. Technetium-99m HL91 uptake as a tumour hypoxia marker: relationship to tumour blood flow. Eur J Nucl Med. 1999;26:91-94.
72. Vavere AL, Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans. 2007;43:4893-4902. (Pubitemid 350015414)
73. Blower PJ, Castle TC, Cowley AR, et al. Structural trends in copper(II) bis(thiosemicarbazone) radiopharmaceuticals. Dalton Trans. 2003;23:4416-4425.
74. Blower PJ, Dilworth JR, Maurer RI, Mullen GED, Reynolds CA, Zheng Y. Towards new transition metal-based hypoxic selective agents for therapy and imaging. J Inorg Biochem. 2001;85:15-22.
75. 4-methylthiosemicarbazone) (Cu- ATSM). Nucl Med Biol. 2005;32:623-630.
76. Cowley AR, Dilworth JR, Donnelly PS, White JM. Copper complexes of thiosemicarbazone-pyridylhydrazine (THYNIC) hybrid ligands: a new versatile potential bifunctional chelator for copper radiopharmaceuticals. Inorg Chem. 2006;45:496-498.
77. Dearling JLD, Lewis JS, Mullen GED, Rae MT, Zweit J, Blower PJ. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med. 1998;25:788-792.
78. Dearling JLJ, Lewis JS, Mullen GED, Welch MJ, Blower PJ. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structureactivity relationships. J Biol Inorg Chem. 2002;7:249-259.
79. Holland JP, Green JC, Dilworth JR. Probing the mechanism of hypoxia selectivity of copper bis(thiosemicarbazonato) complexes: DFT calculation of redox potentials and absolute acidities in solution. Dalton Trans. 2006;(6):783-794.
80. Maurer RI, Blower PJ, Dilworth JR, Reynolds CA, Zheng Y, Mullen GED. Studies on the mechanism of hypoxic selectivity in copper bis(thiosemicarbazone) radiopharmaceuticals. J Med Chem. 2002;45:1420-1431.
81. Taniuchi H, Fujibayashi Y, Yonekura Y, Konishi J, Yokoyama A. Hyperfixation of copper-62-PTSM in rat brain after transient global ischemia. J Nucl Med. 1997;38:1130-1134.
82. 4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med. 2000;14:323-328.
83. 60Cu-ATSM. J Nucl Med. 2008;49:201-205.
84. 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844-850.
85. 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum. 2008;51:1641-1648.
86. 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med. 2008;49:1177-1182.
87. 60Cu-ATSM: relationship to therapeutic response - a preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233-1238.
88. Lewis JS, Welch MJ, Tang L. Workshop on the production, application and clinical translation of "non-standard" PET nuclides: a meeting report. Q J Nucl Med Mol Imaging. 2008;52:101-106.
89. Padhani AR, Krohn KA, Lewis JS, Alber M. Imaging oxygenation of human tumors. Eur Radiol. 2007;17:861-872.
90. Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am. 2005;43:169-187.
91. Koh W-J, Rasey JS, Evans ML. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys. 1992;22:199-212.
92. Rasey JS, Wui-Jin K, Grierson JR, Grunbaum Z, Krohn KA. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys. 1989;17:985-991.
93. 18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging. 2003;30:695-704.
94. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 1996;36:417-428.
95. Rasey JS, Nelson NJ, Chin LK, Evans ML, Grunbaum Z. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res. 1990; 122:301-308.
96. Rajendran JG, Schwartz DL, O'Sullivan J, et al. Tumor hypoxia imaging with [F-18]fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res. 2006;12:5435-5441. (Pubitemid 44497258)
97. 18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res. 2008;14:2623-2630.
98. 18F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70:235-242.
99. 18F]misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol. 2006;24:2098-2104.
100. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med. 1995;22:265-280.
101. 18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 2004;10:2245-2252.
102. 18F-FDG PET. J Nucl Med. 2006;47: 1921-1926.
103. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol. 2008;10:1-18.
104. 11C- methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas. Eur J Nucl Med Mol Imaging. 2006;33:516-524.
105. 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009;73:479-485.
106. 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med. 2008;49:694-699.
107. Ogawa T, Miura S, Murakami M, et al. Quantitative evaluation of neutral amino acid transport in cerebral gliomas using positron emission tomography and fluorine-18 fluorophenylalanine. Eur J Nucl Med. 1996;23:889-895. (Pubitemid 26278787)
108. 18F)fluorotyrosine. J Nucl Med. 1991;32:1338-1346.
109. 18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med. 1999;40: 205-212.
110. 18F]1- amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med. 1999;40:331-338.
111. 18F]FACBC: improved preparation of labeling precursor and automated radiosynthesis. Appl Radiat Isot. 2003;58:657-666.
112. 11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med. 2000;27:542-549.
113. 18F-fluoroethyl)-Ltyrosine in peripheral tumors: first clinical results. J Nucl Med. 2005;46:411-416.
114. 18F-FDG PET and CT in patients with head and neck cancer. J Nucl Med. 2006;47:256-261.
115. 18F-FACBC in humans. J Nucl Med. 2007;48:1017-1020.
116. 18Ffluorocyclobutyl- 1-carboxylic acid for the detection of prostate cancer. J Nucl Med. 2007;48:46-55.
117. 18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48:56-63.
118. 18F fluorodeoxyglucose PET - initial experience. Radiology. 2008;248:599-605.
119. Yoshida Y, Kurokawa T, Sawamura Y, et al. The positron emission tomography with F-18 17beta-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer. Gynecol Oncol. 2007;104:764-766. (Pubitemid 46240263)
120. Moresco RM, Scheithauer BW, Lucignani G, et al. Oestrogen receptors in meningiomas: a correlative PET and immunohistochemical study. Nucl Med Commun. 1997;18:606-615.
121. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 2007;9:R6.
122. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Ann Oncol. 2005;16:1569-1583.
123. Fernandez-Morales LA, Segui MA, Andreu X, et al. Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 status. Clin Breast Cancer. 2007;7:559-564.
124. Steeg PS. Heterogeneity of drug target expression among metastatic lesions: lessons from a breast cancer autopsy program. Clin Cancer Res. 2008;14:3643-3645.
125. 18F]FES) in ER positive breast cancer patients. J Pharm Pharm Sci. 2007;10:256s-265s.
126. Kuukasjarvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol. 1996;14:2584-2589.
127. Zilli M, Grassadonia A, Tinari N, et al. Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer. Biochim Biophys Acta. 2009;1795:62-81.
128. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-5312. (Pubitemid 350232263)
129. 77Br]bromoestradiol: dosimetry and preliminary clinical studies. J Nucl Med. 1982;23:425-430.
130. Mankoff DA, Tewson TJ, Eary JF. Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16 alpha-fluoroestradiol (FES). Nucl Med Biol. 1997;24:341-348.
131. 18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP). Nucl Med Biol. 1999;26:905-913.
132. 18F- fluoroestradiol. J Nucl Med. 2008;49:367-374.
133. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995;36:1766-1774.
134. Mintun MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology. 1988;169:45-48.
135. Regan MM, Viale G, Mastropasqua MG, et al. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst. 2006;98:1571-1581.
136. Kiesewetter DO, Kilbourn MR, Landvatter SW, Heiman DF, Katzenellenbogen JA, Welch MJ. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med. 1984;25:1212-1221.
137. Pomper MG, VanBrocklin H, Thieme AM, et al. 11 Beta-methoxy-, 11 betaethyl- and 17 alpha-ethynyl-substituted 16 alpha-fluoroestradiols: receptorbased imaging agents with enhanced uptake efficiency and selectivity. J Med Chem. 1990;33:3143-3155.
138. 18F]fluoro-17beta-estradiol. J Med Chem. 2005;48:6366-6378.
139. 18F]fluoroestradiol by target tissues in the rat: competition by tamoxifen, and implications for quantitating estrogen receptors in vivo and the use of animal models in receptor-binding radiopharmaceutical development. Nucl Med Biol. 1993;20:735-745.
140. Dehdashti F, Mortimer JE, Trinkaus K, et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat. 2009; 113:509-517.
141. 18F]fluoro-17β-estradiol uptake in metastatic breast carcinoma. J Nucl Med. 1991;32:1526-1531.
142. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24:2793-2799. (Pubitemid 46630578)
143. Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K, Katzenellenbogen JA, Welch MJ. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001;19:2797-2803.
144. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 1999;26:51-56.
145. 18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res. 1996;2:933-939.
146. Hawkin RA, Arends MJ, Ritchie AA, Langdon S, Miller WR. Tamoxifen increases apoptosis but does not influence markers of proliferation in an MCF-7 xenograft model of breast cancer. Breast. 2000;9:96-106.
147. Clark JH, Peck EJ Jr, Anderson JN. Oestrogen receptors and antagonism of steroid hormone action. Nature. 1974;251:446-448.
148. Horwitz KB, McGuire WL. Nuclear mechanisms of estrogen action: effects of estradiol and anti-estrogens on estrogen receptors and nuclear receptor processing. J Biol Chem. 1978;253:8185-8191.
149. Tormey DC, Simon RM, Lippman ME, Bull JM, Myers CE. Evaluation of tamoxifen dose in advanced breast cancer: a progress report. Cancer Treat Rep. 1976;60:1451-1459.
150. Fabian C, Sternson L, Barnett M. Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. Cancer Treat Rep. 1980;64:765-773.
151. Sabnis GJ, Macedo LF, Goloubeva O, Schayowitz A, Brodie AMH. Stopping treatment can reverse acquired resistance to letrozole. Cancer Res. 2008; 68:4518-4524.
152. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
153. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of
154. Gignac GA, Morris MJ, Heller G, Schwartz LH, Scher HI. Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel. Cancer. 2008;113:966-974.
155. Sahi D, Ohlmann C, Cordia I, Engelmann U, Heidenreich A. A flare-up in patients with hormone-refractory prostate cancer (HRPCA) receiving docetaxel- based chemotherapy: incidence and differentiation from progressive disease. Paper presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 2-6, 2006; Atlanta, GA. Abstract 14523.
156. Smith PH, Bono A, Calais da Silva F, et al. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer: a subanalysis of EORTC Trial 30853. The EORTC Urological Group. Cancer. 1990;66:1009-1016. (Pubitemid 20292997)
157. Agus DB, Cordon-Cardo C, Fox W, et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst. 1999;91:1869-1876.
158. 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004;45:366-373.
159. Bonasera TA, O'Neil JP, Xu M, et al. Preclinical evaluation of fluorine-18- labeled androgen receptor ligands in baboons. J Nucl Med. 1996;37:1009-1015. (Pubitemid 126447143)
160. 18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorinationreduction, receptor binding, and tissue distribution. J Med Chem. 1995;38:816-825.
161. Morris MJ, Akhurst T, Larson SM, et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res. 2005;11:3210-3216. (Pubitemid 40627867)
162. Oyama N, Akino H, Suzuki Y, et al. Prognostic value of 2-deoxy-2-[F- 18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol. 2002;4:99-104. (Pubitemid 34272714)
163. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology. 1996;199:751-756.
164. 18F]fluoro-2- deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res. 2005;11:4761-4769.
165. Dehdashti F, Picus J, Michalski JM, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging. 2005;32:344-350. (Pubitemid 40562127)
166. 1H-MRS. J Neurooncol. 2003;62:329-338.
167. 18F-FDG PET. J Nucl Med. 2008;49:1245-1248.
168. 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET. Nucl Med Commun. 2003;24:273-279.
169. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11- choline. J Nucl Med. 1998;39:990-995.
170. Kotzerke J, Prang J, Neumaier B, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med. 2000; 27:1415-1419.
171. 11C-choline positron emission tomography. Eur Urol. 2002;42:18-23.
172. 11C-choline- PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin. 2007;46:161-168.
173. Fanti S, Nanni C, Ambrosini V, Gross MD, Rubello D, Farsad M. PET in genitourinary tract cancers. Q J Nucl Med Mol Imaging. 2007;51:260-271.
174. Fazio F, Picchio M, Messa C. Is 11C-choline the most appropriate tracer for prostate cancer? Eur J Nucl Med Mol Imaging. 2004;31:753-756. (Pubitemid 38647916)
175. 11C-choline PET. J Nucl Med. 2003;44:331-335.
176. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol. 2003;44:32-38.
177. 11C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging. 2007; 34:185-196.
178. 11C-acetate PET imaging of prostate cancer. J Nucl Med. 2002;43:181-186.
179. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med. 2003; 44:549-555.
180. Sandblom G, Sorensen J, Lundin N, Haggman M, Malmstrom P-U. Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology. 2006;67:996-1000.
181. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol. 2006;24:2513-2519.
182. Kotzerke J, Volkmer BG, Neumaier B, Gschwend JE, Hautmann RE, Reske SN. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2002;29:1380-1384.
183. 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2003;30:607-611.
184. 11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med. 2008;49:327-334.
185. 18F-galacto- RGD, a new radiotracer for imaging αvβ3 expression. J Nucl Med. 2006; 47:763-769.
186. 18F-FDG. J Nucl Med. 2008;49:22-29.
187. 18F-AH111585 in breast cancer patients. J Nucl Med. 2008;49:879-886.
188. 18F-FDG PET. J Nucl Med. 2006;47:793-796.
189. 18F-FDG. J Nucl Med. 2005; 46:945-952.